Truist Financial
SRNE

Truist Financial’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Truist Financial’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,650
Closed -$20.1K – 2713
2022
Q4 		$20.1K Hold
22,650
– – ﹤0.01% 2533
2022
Q3 		$36K Hold
22,650
– – ﹤0.01% 2479
2022
Q2 		$45K Buy
+22,650
New +$39.2K ﹤0.01% 2586
2021
Q4 		– Sell
-13,001
Closed -$99K – 2885
2021
Q3 		$99K Sell
13,001
-23,700
-65% -$201K ﹤0.01% 2644
2021
Q2 		$355K Buy
36,701
+4,600
+14% +$36.6K ﹤0.01% 2271
2021
Q1 		$265K Sell
32,101
-4,895
-13% -$51.7K ﹤0.01% 2363
2020
Q4 		$253K Sell
36,996
-4,150
-10% -$33.3K ﹤0.01% 2263
2020
Q3 		$459K Sell
41,146
-9,275
-18% -$84.9K ﹤0.01% 1772
2020
Q2 		$317K Buy
+50,421
New +$193K ﹤0.01% 1913

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Truist Financial's SRNE Position: Q1 2023 in Review

Truist Financial sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 22,650 shares — an estimated $20.1K sold.

Truist Financial first reported a position in SRNE in Q2 2020 and held it in 9 quarters. The position peaked at $459K in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Truist Financial reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Truist Financial sold 22,650 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $20.1K.
  • Truist Financial first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 9 quarters.
  • Truist Financial's Sorrento Therapeutics, Inc. position peaked at $459K in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Truist Financial's 13F filing for Q1 2023, filed 5 May 2023.